The EMA Committee for Medicinal Products for Human Use will evaluate the anti-Covid-19 vaccine developed by Janssen, a subsidiary of Johnson & Johnson. The manufacturer submitted an authorization request to it on February 16. The EMA hopes to be able to give an opinion by mid-March.
The vaccine candidate will be evaluated on an accelerated schedule. The European Medicines Agency began in early December 2020 to analyze the data from the trials carried out on this vaccine as part of a “rolling” review.
Three COVID-19 vaccines are already available in the European Union. They are manufactured by the alliance of Pfizer and BioNTech, by Moderna and by AstraZeneca.
The one from Johnson & Johnson, which uses a modified adenovirus, is a single-dose vaccine that can be stored for several months in a “conventional” refrigerator. Europe has pre-ordered 200 million doses of it in the summer of 2020.
(Pushkala Aripaka in Bangalore; French version Bertrand Boucey, edited by Jean-Michel Bélot)
Source: UsineNouvelle – Actualités A la une by www.usinenouvelle.com.
*The article has been translated based on the content of UsineNouvelle – Actualités A la une by www.usinenouvelle.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!